AVIR Q2 2024 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$104,000

Operating Income

-$47M

Net Income

-$41M

EPS (Diluted)

$-0.48

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$42M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$510M

Total Liabilities

$34M

Stockholders' Equity

$476M

Cash & Equivalents

$243M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$104,000	-$16M	+99.4%
Operating Income	-$47M	-$35M	-33.2%
Net Income	-$41M	-$28M	-43.8%